1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
The Exploration – Hypothesis Development Award supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the TSC research field. The studies supported by this award mechanism are expected to generate preliminary data for future avenues of scientific investigation. The proposed research project should include a well-formulated, testable hypothesis based on a strong scientific rationale and study design. Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis.The following are important aspects of the Exploration – Hypothesis Development Award:Innovation: Innovative research may introduce a new paradigm, challenge existing paradigms, examine existing problems from new perspectives, or exhibit other highly creative qualities. Research that is an incremental advance upon published data is not considered innovative and is not consistent with the intent of the award mechanism.Although not all-inclusive, the following examples are ways in which the proposed research project may be innovative:○ Explores a novel idea and/or research question in TSC research and/or patient care.○ Uses or develops novel methods or technologies to address a question in TSC research and/or patient care.○ Applies or adapts existing methods or technologies for novel TSC research or clinical purposes that differ fundamentally from those originally intended. Impact: The primary goal of this mechanism is to pioneer transformative research that could lay the foundation for a new direction in the field of TSC.
Funding Opportunity Number: W81XWH-22-TSCRP-EHDA. Assistance Listing: 12.420. Funding Instrument: CA,G. Category: ST. Award Amount: $1.4M total program funding.
Get alerted about grants like this
Get emailed when new opportunities from “Dept. of the Army -- USAMRAA” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility. Confirm the full requirements in the official notice before applying.
The current listing shows $1.4M total program funding. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was July 28, 2022, which has passed. Check the official notice for any future application windows before investing time in a proposal.
Yes — DOD, Tuberous Sclerosis Complex Research Program, Exploration – Hypothesis Development Award is offered by Dept. of the Army -- USAMRAA and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
To increase research capacity for NF, the NFRP is offering the NFRA. The intent of the NFRA is to provide a framework of intensive mentoring and iterative guidance with proposed research, national networking, collaborations, and a peer group of junior faculty (Scholars). The NFRP NFRA will bring together established NF investigators (one Director and one Deputy Director) and early-career independent investigators (Scholars) and their Career Guides to develop successful, highly productive NF scientists and clinicians that will conduct research with the aim of lessening the clinical impact of NF1, NF2, and schwannomatosis. The NFRA is a multi-institutional interactive virtual academy platform designed to offer support to NFRA Scholars with the goal to advance innovative, high impact NF research through a collaborative and career development environment.The functioning NFRA will consist of Scholars and their Career Guides (mentors) from different institutions, and an Academy Director and Deputy Director (see Figure 1 below). The Academy Director and Deputy Director will catalyze the growth and professional development of the Scholars in collaboration with their Career Guides, assess the progress of the Scholars, and facilitate communication and collaboration among all Academy members. The Career Guide is not required to be at the same institution as the Scholar; however, if the (primary) Career Guide is from a different institution, a secondary Career Guide at the Scholar’s institution is needed. The NFRA will afford Scholars opportunities to operate in a collegial, highly dynamic, and cutting-edge center to move early-career investigators towards positions as leaders in NF conducting impactful research.During this first phase of the academy, the NFRP is offering the FY24 NFRALA funding opportunity to solicit applications for an Academy Director and Deputy Director to lead the NFRA. The Academy Director and Deputy Director (referred to as Academy Leadership) must be established NF researchers and can be at different institutions. The Academy Leadership must demonstrate a strong record of mentoring and training early-career independent investigators, a commitment to leadership, the ability to articulate methods toward research collaborations, and the ability to objectively assess the progress of all Scholars in the NFRA. An objective of the NFRA leadership team is to establish the Academy structure in its first year and in subsequent years, conduct oversight of this activity. Other objectives will include execution of research that will engage NFRA FY25 Scholars (including subsequent-year Scholars), develop tools for Scholars to enable success, and provide opportunities to broaden their knowledge in NF disorders. The leadership team will identify and offer opportunities to network with other NFRP FY25 Early Investigator Research Award recipients (and subsequent year awardees) and NFRP FY25 New Investigator Award – Early-Stage Investigator (NIA – ESI) Award recipients (and subsequent year awardees). In the second stage of the academy, the NFRP anticipates release of funding opportunities for the Scholars who will conduct their research under the guidance of the NFRA leadership team. Funding Opportunity Number: HT942524NFRPNFRALA. Assistance Listing: 12.420. Funding Instrument: CA,G. Category: ST. Award Amount: $1.5M total program funding.
Summary: The fiscal year 2026 (FY26) Kidney Cancer Research Program (KCRP) Concept Award supports highly innovative, untested, potentially groundbreaking concepts, theories, paradigms and/or basic kidney cancer research. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation in kidney cancer. Applications must describe how the new concept will be innovative and present a novel course of investigation in the field of kidney cancer. Distinctive Features: • Preliminary data are not allowed. • This is a blinded funding mechanism. Applications to this funding opportunity will undergo a double-blinded peer review. Applications must not include any materials that may identify the Principal Investigator (PI), a collaborator, or the organization of the PI or collaborator. • Due to the blinded nature of the review process, identifying or making references to the PI, collaborator(s), or their organization(s) in the proposal (Project Narrative, List of Abbreviations, Acronyms, Symbols, Statement of Work, Impact Statement and Innovation Statement) is prohibited and will result in administrative rejection of the application. Funding Opportunity Number: HT942526KCRPCA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $840K total program funding.
Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Clinical Translational Research Award (CTRA) supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis or treatment of tuberous sclerosis complex (TSC).Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI(s) application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn. Funding Opportunity Number: HT942526TSCRPCTRA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $3.5M total program funding.
Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Exploration-Hypothesis Development Award (EHDA) supports the initial exploration of innovative, high-risk, high-gain and potentially groundbreaking concepts in the tuberous sclerosis complex (TSC) research field.Distinctive Features: Preliminary Data is not required. Applications should demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. Funding Opportunity Number: HT942526TSCRPEHDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.1M total program funding.
Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Idea Development Award (IDA) supports conceptually innovative and high-impact research that could ultimately lead to critical discoveries in tuberous sclerosis complex (TSC) research and/or improvements in patient care.Distinctive Features: This funding mechanism allows for established and new-to-the-field investigators. New-to-the-field investigators are independent investigators that are early in their faculty appointments and/or established investigators transitioned from other research fields into TSC research. Applications to the New-to-the-Field option will compete separately from the Established Investigators submitting to the regular Idea Development Award (IDA). Funding Opportunity Number: HT942526TSCRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $3.2M total program funding.
After SBIR reauthorization, the U.S. Army released five new small-business topics under Army FUZE — Ka-Band metamaterial radar, a Li-ion 6T battery open topic, in-transit-visibility blockchain, modular UAS payloads, and the xTech|Phantum prize competition. Awards run from $150K to $300K per Phase I. But the bigger story is the Army's shift from funding parts to funding whole systems. Here is what each topic funds and how to compete.
Read articleDARPA transferred its first autonomous-ready H-60Mx Black Hawk to the Army on March 20, capping a decade of ALIAS research. Now the same technology underpins an SBIR XL opportunity for small businesses building wildfire autonomy.
Read article